Karyopharm Submits XPOVIO Application to FDA for Myelofibrosis Treatment

Karyopharm Therapeutics Inc. has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for XPOVIO (selinexor) combined with ruxolitinib to treat myelofibrosis patients. The company is seeking Priority Review, which could accelerate the FDA's decision to within six months. This submission is supported by data from the Phase 3 SENTRY trial, potentially expanding treatment options for this condition.